Real-world occurrence, therapy, and outcome of patients with class 2 or 3 BRAF compared with class 1 BRAF-mutated cancers by S. Pradervand, N. Freundler, B. Gosztonyi, L. Roncoroni, R. Achermann, T. Schwenk, G. de Fraipont, J. Garessus, S. Haefliger, A.B. Leichtle, M.K. Kiessling, T. Mueller-Focke, F.S. Krebs, V. Zoete, P. Tsantoulis, O. Michielin, C. Britschgi, A. Wicki

Get full text